Article
Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance.
Antimicrobial agents and chemotherapy - 1 Feb 2011
Louie A, Heine H S, VanScoy B, Eichas A, Files K, Fikes S, Brown D L, Liu W, Kinzig-Schippers M, Sörgel F, Drusano G L
Abstract excerpt
Yersinia pestis, the causative agent of bubonic, septicemic, and pneumonic plague, is classified as a CDC category A bioterrorism pathogen. Streptomycin and doxycycline are the "gold standards" for the treatment of plague. However, streptomycin is not available in many countries, and Y. pestis isolates resistant to streptomycin and doxycycline occur naturally and have been generated in laboratories. Moxifloxacin...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.